Vienna, August 19. Doctor in Sciences María del Carmen Domínguez, head of the Autoimmunity and Inflammation project of the Center for Genetic Engineering and Biotechnology of Cuba, presented in plenary session of the 19th World Congress of Immunology the Cuban experience in the research of autoimmune diseases, particularly rheumatoid arthritis.
This project that the scientist directs generated the development of Jusvinza, a drug registered for this pathology and which had an emergency authorization in our country for the treatment of severe forms of COVID-19.
In the conference, the doctor explained the rationale for the design of Jusvinza, and the results that explain the mechanism of action of Jusvinza and its approach based on the induction of immunological tolerance were presented.
The 19th International Congress of Immunology organized by the International Union of Immunological Societies (IUIS) will be held in Vienna from August 17 to 22, 2025.
Cuba has prestigious scientific institutions such as the Center for Genetic Engineering and Biotechnology, the Center for Molecular Immunology and the Finlay Vaccine Institute, which have contributed so much over the years to the health of Cubans and other peoples.